Molecular pathological classification of colorectal cancer

作者：Muller Mike F; Ibrahim Ashraf E K; Arends Mark J^*

来源：Virchows Archiv, 2016, 469(2): 125-134.

DOI：10.1007/s00428-016-1956-3

• Colorectal
• Cancer
• Polymerase epsilon
• Ultramutant
• Hypermutant
• Defective mismatch repair
• Microsatellite instability
• Chromosomal instability
• Mutation
• Somatic copy number alterations
• Consensus molecular subtypes
• The Cancer Genome Atlas
• Serrated pathway

Colorectal cancer (CRC) shows variable underlying molecular changes with two major mechanisms of genetic instability: chromosomal instability and microsatellite instability. This review aims to delineate the different pathways of colorectal carcinogenesis and provide an overview of the most recent advances in molecular pathological classification systems for colorectal cancer. Two molecular pathological classification systems for CRC have recently been proposed. Integrated molecular analysis by The Cancer Genome Atlas project is based on a wide-ranging genomic and transcriptomic characterisation study of CRC using array-based and sequencing technologies. This approach classified CRC into two major groups consistent with previous classification systems: (1) similar to 16 % hypermutated cancers with either microsatellite instability (MSI) due to defective mismatch repair (similar to 13 %) or ultramutated cancers with DNA polymerase epsilon proofreading mutations (similar to 3 %); and (2) similar to 84 % non-hypermutated, microsatellite stable (MSS) cancers with a high frequency of DNA somatic copy number alterations, which showed common mutations in APC, TP53, KRAS, SMAD4, and PIK3CA. The recent Consensus Molecular Subtypes (CMS) Consortium analysing CRC expression profiling data from multiple studies described four CMS groups: almost all hypermutated MSI cancers fell into the first category CMS1 (MSI-immune, 14 %) with the remaining MSS cancers subcategorised into three groups of CMS2 (canonical, 37 %), CMS3 (metabolic, 13 %) and CMS4 (mesenchymal, 23 %), with a residual unclassified group (mixed features, 13 %). Although further research is required to validate these two systems, they may be useful for clinical trial designs and future post-surgical adjuvant treatment decisions, particularly for tumours with aggressive features or predicted responsiveness to immune checkpoint blockade.

• 出版日期2016-8